Barron's (blog) | AbbVie: No Upside For Hep-C, Little Upside For Stock, Morgan Stanley Says Barron's (blog) Elotuzumab, for instance, is partnered with Bristol-Myers Squibb (BMY), while Daclizumab is being developed with Biogen Idex (BIIB). Shares of AbbVie, which were removed from Goldman Sachs conviction buy list earlier this month, have dropped 3.1% to ... |
